DE602004028769D1 - Verbesserte Sekretion von Neublastin - Google Patents

Verbesserte Sekretion von Neublastin

Info

Publication number
DE602004028769D1
DE602004028769D1 DE602004028769T DE602004028769T DE602004028769D1 DE 602004028769 D1 DE602004028769 D1 DE 602004028769D1 DE 602004028769 T DE602004028769 T DE 602004028769T DE 602004028769 T DE602004028769 T DE 602004028769T DE 602004028769 D1 DE602004028769 D1 DE 602004028769D1
Authority
DE
Germany
Prior art keywords
neublastin
construct
region
nervous system
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004028769T
Other languages
English (en)
Inventor
Lars Ulrik Wahlberg
Mette Groenborg
Philip Kusk
Jens Tornoee
Nels E Pederson
William P Sisk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NsGene AS
Biogen Inc
Biogen MA Inc
Original Assignee
NsGene AS
Biogen Idec Inc
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NsGene AS, Biogen Idec Inc, Biogen Idec MA Inc filed Critical NsGene AS
Publication of DE602004028769D1 publication Critical patent/DE602004028769D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602004028769T 2003-06-10 2004-06-10 Verbesserte Sekretion von Neublastin Expired - Lifetime DE602004028769D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200300861 2003-06-10
US50748303P 2003-10-02 2003-10-02

Publications (1)

Publication Number Publication Date
DE602004028769D1 true DE602004028769D1 (de) 2010-09-30

Family

ID=34485959

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602004028769T Expired - Lifetime DE602004028769D1 (de) 2003-06-10 2004-06-10 Verbesserte Sekretion von Neublastin
DE602004019524T Expired - Lifetime DE602004019524D1 (de) 2003-06-10 2004-06-10 Verbesserte sezernierung von neublastin

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE602004019524T Expired - Lifetime DE602004019524D1 (de) 2003-06-10 2004-06-10 Verbesserte sezernierung von neublastin

Country Status (17)

Country Link
US (1) US7601518B2 (de)
EP (2) EP2058329B1 (de)
JP (1) JP5623685B2 (de)
KR (1) KR20060031618A (de)
CN (1) CN100475846C (de)
AT (2) ATE423134T1 (de)
AU (1) AU2004245175C1 (de)
BR (1) BRPI0411243A (de)
CA (1) CA2527914C (de)
DE (2) DE602004028769D1 (de)
DK (2) DK1636260T3 (de)
ES (2) ES2323066T3 (de)
HK (1) HK1082752A1 (de)
IL (1) IL172270A (de)
NZ (1) NZ544263A (de)
RU (1) RU2005138368A (de)
WO (1) WO2004108760A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
EP1897552B1 (de) 2003-04-18 2009-06-17 Biogen Idec MA Inc. Polymerkonjugiertes glycosiliertes Neublastin
EP2281877A3 (de) 2003-05-21 2011-06-01 Genzyme Corporation Verfahren zur herstellung von präparationen rekombinanter aav-virionen, die weitgehend frei von leeren capsiden sind
EP2058329B1 (de) 2003-06-10 2010-08-18 NsGene A/S Verbesserte Sekretion von Neublastin
US7598059B2 (en) * 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
US20060239966A1 (en) * 2003-10-20 2006-10-26 Tornoee Jens In vivo gene therapy of parkinson's disease
WO2006023782A2 (en) 2004-08-19 2006-03-02 Biogen Ideca Ma Inc. Refolding transforming growth factor beta family proteins
CN102924585A (zh) * 2004-08-19 2013-02-13 比奥根艾迪克Ma公司 神经胚素变体
EP1915394B1 (de) 2005-05-20 2021-01-27 Lonza Biologics plc. Expression auf hohem niveau von rekombinantem antikörper in einer säugetier-wirtszelle
EP1937295A2 (de) * 2005-10-11 2008-07-02 NS Gene A/S Behandlung von retinopathien mit gfr3-agonisten
US9265814B2 (en) * 2005-12-30 2016-02-23 Neurotech Usa, Inc. Micronized device for the delivery of biologically active molecules and methods of use thereof
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
EP1993590B1 (de) * 2006-03-01 2013-12-25 Biogen Idec MA Inc. Zusammensetzungen und verfahren zur verabreichung von proteinen der gdnf-liganden-familie
ES2476253T3 (es) 2007-05-01 2014-07-14 Biogen Idec Ma Inc. P�ptidos de neublastina para su uso en el aumento de la vascularizaci�n en tejido con flujo sanguíneo deteriorado
EP2048237A1 (de) 2007-10-05 2009-04-15 Avir Green Hills Biotechnology Research Development Trade Ag Replikationsdefizienter Influenza-Virus zur Expression heterologer Sequenzen
CN101688222B (zh) * 2007-06-29 2013-03-06 弗·哈夫曼-拉罗切有限公司 启动子
EP2205634A2 (de) * 2007-08-08 2010-07-14 Biogen Idec MA, Inc. Anti-neublastin-antikörper und anwendungen davon
WO2009117740A2 (en) * 2008-03-21 2009-09-24 Tissuegene, Inc. Treatment of intervertebral disc degeneration
EP2281047B1 (de) 2008-04-15 2020-04-08 Genzyme Corporation Verfahren zur herstellung des rod-derived cone viability-faktors (rdcvf)
JP5897335B2 (ja) 2009-01-23 2016-03-30 エヌエスジーン・アクティーゼルスカブＮｓＧｅｎｅ Ａ／Ｓ 改良された細胞株及びカプセル化細胞生体送達におけるその使用
WO2010083842A2 (en) 2009-01-23 2010-07-29 Nsgene A/S Expression of neuropeptides in mammalian cells
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
LT2691530T (lt) 2011-06-10 2018-08-10 Oregon Health & Science University Cmv glikoproteinai ir rekombinantiniai vektoriai
ES2947311T3 (es) * 2015-05-07 2023-08-04 Univ South Florida Gen UBE3A modificado para un enfoque de terapia génica para el síndrome de Angelman
GB201519086D0 (en) * 2015-10-28 2015-12-09 Syncona Partners Llp Gene Therapy
EP3423097A4 (de) * 2016-03-04 2019-08-21 NGM Biopharmaceuticals, Inc. Zusammensetzungen und verfahren zur modulation des körpergewichts
CN108610398B (zh) * 2018-01-15 2020-08-11 武汉海特生物制药股份有限公司 一段功能序列及在分泌蛋白表达中的应用
EP3749754A4 (de) 2018-02-08 2021-10-20 Applied Stemcell, Inc. Verfahren für das screening von varianten eines zielgens
US20220048984A1 (en) * 2018-12-21 2022-02-17 Gloriana Therapeutics Sarl Mammalian Cell Culture-Produced Neublastin Antibodies

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
JP2703893B2 (ja) 1985-07-05 1998-01-26 ホワイトヘッド・インスティテュ−ト・フォ−・バイオメディカル・リサ−チ 外来遺伝子物質を発現する上皮細胞
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
EP0378576B1 (de) 1987-09-11 1995-01-18 Whitehead Institute For Biomedical Research Transduktionsveränderte fibroblasten und ihre anwendung
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5156844A (en) 1987-11-17 1992-10-20 Brown University Research Foundation Neurological therapy system
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5487739A (en) 1987-11-17 1996-01-30 Brown University Research Foundation Implantable therapy systems and methods
JP2791418B2 (ja) * 1987-12-02 1998-08-27 株式会社ミドリ十字 異種蛋白質の製造方法、組換えｄｎａ、形質転換体
DE3829752A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration
DE3829766A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Verfahren zur herstellung von membranen
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
IL95330A0 (en) * 1989-08-11 1991-06-30 Lilly Co Eli Expression of a functional insect specific toxin gene in mammalian cells
CA2109085C (en) 1991-04-25 2003-03-11 Keith E. Dionne Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
HU220795B1 (hu) 1991-09-20 2002-05-28 Amgen Inc. Gliasejtvonal-eredetű neurotróf faktorfehérjék, továbbá berendezések és gyógyászati készítmények idegsejtkárosodás megelőzésére és kezelésére
US5512600A (en) 1993-01-15 1996-04-30 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
AU688776B2 (en) 1993-06-23 1998-03-19 Brown University Research Foundation Method and apparatus for sealing implantable, membrane encapsulation devices
DE69430824T2 (de) 1993-08-12 2003-01-23 Neurotech Sa Biokompatible immunoisolatorische Kapseln, die genetisch veränderte Zellen enthalten
WO1995024929A2 (en) 1994-03-15 1995-09-21 Brown University Research Foundation Polymeric gene delivery system
US5550050A (en) 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US5656465A (en) 1994-05-04 1997-08-12 Therion Biologics Corporation Methods of in vivo gene delivery
US5677158A (en) 1995-06-07 1997-10-14 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US5739307A (en) 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US5904144A (en) 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
US6027721A (en) 1996-05-20 2000-02-22 Cytotherapeutics, Inc. Device and method for encapsulated gene therapy
US6054142A (en) 1996-08-01 2000-04-25 Cyto Therapeutics, Inc. Biocompatible devices with foam scaffolds
US6136597A (en) 1997-09-18 2000-10-24 The Salk Institute For Biological Studies RNA export element
EP1053002A1 (de) * 1998-02-10 2000-11-22 Oregon Health Sciences University Behandlung von knochendefekten osteoblast-vorläuferzellen
US6303136B1 (en) 1998-04-13 2001-10-16 Neurotech S.A. Cells or tissue attached to a non-degradable filamentous matrix encapsulated by a semi-permeable membrane
US6683058B1 (en) 1998-04-15 2004-01-27 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
DE69940899D1 (de) 1998-05-27 2009-06-25 Genzyme Corp AAV Vektoren zur Herstellung der Medikamente zur konvektion-erhöhten Verabreichung
US6593133B1 (en) 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US20020055467A1 (en) 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
SI1640381T1 (sl) 1998-07-14 2014-07-31 Janssen Pharmaceutica Nv Nevrotropski rastni faktor
US20020002269A1 (en) 1998-09-29 2002-01-03 Jeffrey D. Milbrandt Artemin, a neurotrophic factor
IL126562A0 (en) * 1998-10-14 1999-08-17 Interpharm Lab Ltd Expression and secretion of icil-1 receptor antagonist type ii
US6361741B1 (en) 1999-02-01 2002-03-26 Alcoa Inc. Brazeable 6XXX alloy with B-rated or better machinability
US6420345B1 (en) * 1999-03-01 2002-07-16 Cell Genesys, Inc. Methods and reagents for inhibiting angiogenesis
US6361771B1 (en) * 1999-04-06 2002-03-26 Neurotech S.A. ARPE-19 as a platform cell line for encapsulated cell-based delivery
PT1223966E (pt) 1999-10-29 2003-09-30 Biopharm Ges Biotechn Entwickl Utilizacao do gdnf para tratamento de defeitos na cornea
US6866851B1 (en) * 1999-12-28 2005-03-15 Washington University GFRα1-RET specific agonists and methods therefor
US20020037281A1 (en) 2000-05-26 2002-03-28 Davidson Beverly L. Methods of transducing neural cells using lentivirus vectors
GB0018876D0 (en) * 2000-08-01 2000-09-20 Applied Research Systems Method of producing polypeptides
IL156559A0 (en) * 2000-12-22 2004-01-04 Genentech Inc New use of artemin, a member of the gdnf ligand family
GEP20063916B (en) 2001-02-01 2006-09-11 Biogen Idec Inc Polymer conjugates of neublastin and methods of using same
NZ529126A (en) * 2001-03-28 2010-07-30 Biogen Idec Inc Use of neublastin polypeptides for treating allodynia, hyperalgesic pain and phantom pain
EP1897552B1 (de) * 2003-04-18 2009-06-17 Biogen Idec MA Inc. Polymerkonjugiertes glycosiliertes Neublastin
EP2058329B1 (de) 2003-06-10 2010-08-18 NsGene A/S Verbesserte Sekretion von Neublastin
US7598059B2 (en) * 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
DK1677833T3 (da) 2003-10-20 2010-05-17 Nsgene As Virusvektor til anvendelse til in vivo-genterapi af Parkinsons sygdom

Also Published As

Publication number Publication date
EP1636260A2 (de) 2006-03-22
ATE423134T1 (de) 2009-03-15
AU2004245175B2 (en) 2009-10-15
BRPI0411243A (pt) 2006-07-11
US7601518B2 (en) 2009-10-13
IL172270A0 (en) 2006-04-10
JP2007535898A (ja) 2007-12-13
ES2323066T3 (es) 2009-07-06
CA2527914A1 (en) 2004-12-16
EP2058329A1 (de) 2009-05-13
DK2058329T3 (da) 2010-12-06
US20050089960A1 (en) 2005-04-28
ES2353457T3 (es) 2011-03-02
EP2058329B1 (de) 2010-08-18
DE602004019524D1 (de) 2009-04-02
CA2527914C (en) 2014-10-28
NZ544263A (en) 2009-04-30
DK1636260T3 (da) 2009-06-22
ATE478092T1 (de) 2010-09-15
IL172270A (en) 2015-04-30
RU2005138368A (ru) 2006-07-27
HK1082752A1 (en) 2006-06-16
KR20060031618A (ko) 2006-04-12
EP1636260B1 (de) 2009-02-18
AU2004245175C1 (en) 2010-03-18
WO2004108760A2 (en) 2004-12-16
JP5623685B2 (ja) 2014-11-12
CN1835971A (zh) 2006-09-20
WO2004108760A3 (en) 2005-04-07
CN100475846C (zh) 2009-04-08
AU2004245175A1 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
DE602004028769D1 (de) Verbesserte Sekretion von Neublastin
ATE352626T1 (de) Polypeptide mit galaktoseoxidaseaktivität und dafür kodierende nukleisäuren
ATE414775T1 (de) Polypeptide mit prolyldipeptidylaminopeptidase- aktivität und dafür kodierende nukleinsäuren
WO2004067706A3 (en) Production of multimeric proteins
ATE489458T1 (de) Detoxifizym mit aktivität zur transformation von aflatoxin sowie das dafür codierende gen
AR096027A2 (es) Proteínas insecticidas quiméricas de bacillus thuringiensis
ATE319818T1 (de) Polypeptide mit aminopeptidaseaktivität und für diese kodierende nukleinsäuren
ATE408016T1 (de) Verfahren zur herstellung und sekretion modifizierter peptide
DE69738483D1 (de) Polypeptide mit phytase-aktivität und sie kodierende nukleinsäuren
ATE443074T1 (de) Zubereitungen und methoden zur verwendung in rekombinatorischem klonen von nukleinsäuren
DE69434292D1 (de) Für adseverin kodierendes gen
ATE469217T1 (de) Den phosphorsäure-metabolismus, den kalzium- metabolismus, verkalkung und den vitamin d- metabolismus kontrollierende polypeptide sowie für diese kodierende dna-moleküle
DE60043428D1 (de) POLYPEPTIDE MIT VERZWEIGUNGSENZYM-AKTIVITäT UND FüR DIESE KODIERENDE NUKLEINSäUREN
ATE536409T1 (de) Unkrautbekämpfungsstoffwechselproteine, gene dafür und ihre verwendung
WO2006042719A3 (de) Polypeptid mit phytaseaktivität und dieses codierende nucleotidsequenz
ATE358725T1 (de) Polypeptide mit aminopeptidaseaktivität und dafür kodierende nukleinsäuren
WO2005067410A3 (en) Synthetic nucleic acids from aquatic species
DE60330579D1 (de) Mikrobielle trypsinvarianten mit chymotrypsinaktivität und diese codierende nukleinsäuren
ATE465259T1 (de) Für das dapc-gen kodierende nukleotidsequenzen und verfahren zur herstellung von l-lysin
HUP0003564A2 (hu) Protein kinázok és alkalmazásuk
KR880701073A (ko) 제조합 dna 기법에 의해 생성된 민악티빈
DE60026049D1 (de) POLYPEPTIDE MIT GLUCANOTRANSFERASE AKTIVITÄT UND DAFüR KODIERENDE NUKLEINSÄUREN
DE602004019556D1 (de) Neues plexin-polypeptid, dieses codierende dna und verwendung davon
DE60026569D1 (de) Zusammensetzungen auf der basis von gfr-alpha-4 und deren anwendungen
EP1780275A4 (de) Polypeptid mit einer delta-5-fettsäure-unsättigungsaktivität, für das polypeptid codierendes polynukleotid und verwendung davon